The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat

Pharmacological Research

Volumn 39, Issue 5, 1999, Pages 349-356

  Tanira, Musbah O M ^a   Furman, Brian L ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Extrapancreatic; Glibenclamide; Gliclazide; Insulin; Metabolism

Indexed keywords

FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033136380     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0446     Document Type: Article

References (27)

1. Crepaldi G, Del Prato S. What therapy do our NIDDM patients need? Insulin releasers. Diabetes Res Clin Pract 1995; 28 Suppl: S159-65.
2. Ashcroft FM. Mechanisms of the glycaemic effects of sulphonylureas. Horm Metabol Res 1996; 28: 456-3.
3. Musbah MO, Furman BL. In vitro metabolic effects of gliclazide and glibenclamide in the rat. J Pham Pharmacol 1980; 32: 550-3.
4. Stocks AE, Ma A, Howlett V, Cameron DP. Lack of effect of glibenclamide on insulin requirements and diabetic control in persons with insulin-dependent diabetes. Med J Aust 1988; 149: 472-3.
5. Feldman JM, Lebovitz HE. Appraisal of the extrapancreatic actions of sulfonylureas. Arch Int Med 1969; 123: 314-22.
6. Kolterman QG, Gray RS, Shapiro G, Scarlett JA, Grifin J, Olfskey JM. The acute and chronic effect of sulphonylurea therapy in Type II diabetic patients. Diabetes 1984; 33: 346-54.
7. Müller G, Satoh Y, Geisen K. Extrapancreatic effects of sulphonylureas - A comparison between glimepiride and conventional sulphonylureas. Diabetes Res Clin Pract 1995; 28 Suppl: S115-37.
8. Larkins RG, Jerums G, Taft JI, Gudfrey H, Smith IL, Martin TJ. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: A 2-year controlled study. Diabetes Res Clin Pract 1988; 4: 81-7.
9. Jerums G, Murray RM, Seeman E, Cooper ME, Edgley S, Marwick K, Larkins RG, Martin TJ. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: A 2-year controlled study. Diabetes Res Clin Pract 1987; 3: 71-80.
10. Standing VF, Foy JM. The effect of glibenclamide on glucose uptake in isolated rat diaphragms. Post Grad Med J 1970; (Dec. Suppl.): 16-20.
11. Rogers BJ, Standaert ML, Polett RJ. Direct effects of sulphonylurea agents on glucose transport in the BC3H-1 myocyte. Diabetes 1987; 36: 1292-6.
12. Cooper RD, Vila MC, Watson JE, Nair G, Pollet RJ, Standaert M, Farese RV. Sulphonylurea-stimulated glucose transport association with diacylglycerol-like activation of protein kinase C in BC3H-1 myocytes. Diabetes 1990; 39: 1399-1407.
13. Farese RV, Ishizuka T, Standaert ML, Cooper DR. Sulphonylureas activate glucose transport and protein kinase C in rat adipocytes. Metabolism 1991; 40: 196-400.
14. Jacobs DB, Hayes GR, Lockwood DH. In vitro effects of sulphonylurea on glucose transport and translocation of glucose transporters in adipocytes from streptozotocin-induced diabetic rats. Diabetes 1989; 38: 205-11.
15. Belfiore F, Rabuazzo AM, Iannello S, Campione R, Castorina S, Urzi F. Extrapancreatic action of glibenclamide in man: Reduction in vitro of the inhibitory effect of glucagon and epinephrine on the hepatic key glycolytic enzymes phosphofructokinase (PFK) and pyruvate kinase (PK). Eur J Clin Invest 1989; 19: 367-71.
16. Mulder H, Schopman W Sr, Van der Laly AJ. Extrapancreatic insulin effect of glibenclamide. Ear J Clin Pharmacol 1991; 40: 379-81
17. Garrel DR, Ricq R, Bajard L, Harfouche M, Tourniaire J. Acute effect of glyburide on insulin sensitivity in type I diabetic patients. J Clin Endocrinol Metab 1987; 65: 896-900.
18. McGuiness OP. Discussion 51S-53S.
19. Cherrington AR. Effect of glyburide on hepatic glucose metabolism. Am J Med 1990; 89: 26S-37S.
20. Luzi L, Pozza G. Glibenclamide: An old drug with a novel mechanism of action? Acta Diabetol 1997; 34: 239-44.
21. Malaisse WJ, Leclerq-Meyer V. Insulinotropic action of a new sulphonylurea: Gliclazide. Eur J Clin Biol Res 1972; 17: 310-14.
22. Colwell AR, Jr. Potentiation of insulin action on the liver by tolbutamide. Metabolism 1964; 13: 1310-17.
23. Blumenthal SA. Potentiation of the hepatic action of insulin by tolbutamide. Diabetes 1977; 26: 485-9.
24. Tsiani E, Ramlal T, Leiter LA, Klip A, Fantus IG. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulphonylureas gliclazide and glyburide. Endocrinology 1995; 136: 2505-12.
25. Reaven GM, Dray J. Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus. Diabetes 1967; 16: 487-92.
26. Duchworth WC, Solomon SS, Kitabchi AE. Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 1972; 35: 585-91.
27. Lebovitz HE, Feinglos MN, Bucholtz K, Lebovitz FL. Potentiation of insulin action: A possible mechanism for the antidiabetic action of sulfonylurea drugs. J Clin Endocrinol Metab 1977; 45: 601-4.